Log in

Relevant bibliographies by topics / Pneumococcal vaccine / Dissertations / Theses

To see the other types of publications on this topic, follow the link: Pneumococcal vaccine.

Dissertations / Theses on the topic 'Pneumococcal vaccine'

Author: Grafiati

Published: 4 June 2021

Last updated: 25 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 dissertations / theses for your research on the topic 'Pneumococcal vaccine.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse dissertations / theses on a wide variety of disciplines and organise your bibliography correctly.

1

Lee, Lai-ka, and 李勵嘉. "The pattern of invasive pneumococcal disease in Hong Kong, other parts of China, United States and Thailand : a focus on impact of pneumococcal vaccination : a systematic review." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2014. http://hdl.handle.net/10722/206944.

Full text

Abstract:

Objectives: By summarizing and comparing the pattern of invasive pneumococcal disease (IPD) in the 4 areas (namely Hong Kong, other parts of China, United States and Thailand) at different stages of implementation of universal pneumococcal vaccination, a snapshot picture could be obtained to visualize how pneumococcal vaccination has impacted upon various important measures, including the burden of IPD, prevalent serotypes, antimicrobial resistance, risk factors of IPD, to guide us on the next step to optimize our ability to combat against IPD. Methods: To achieve the objective, a systemati

APA, Harvard, Vancouver, ISO, and other styles

2

Wu, Yunyan, and 吴云燕. "The immunogenicity and safety of 13-valent pneumococcal conjugate vaccine: a systematic review." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2011. http://hub.hku.hk/bib/B46943493.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Fan, Hiu-yan, and 樊曉欣. "Economic evaluation of the second generation pneumococcal conjugate vaccine in children : a systematic review." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2014. http://hdl.handle.net/10722/206903.

Full text

Abstract:

Background Pneumococcal disease, caused by Streptococcus pneumoniae (S. pneumoniae), leads to a great burden of morbidity and mortality globally, especially in developing countries. World Health Organization (WHO) estimated that 476,000 out of 8.8 million global annual deaths in children under 5 years old in 2008 were due to pneumococcal infection. Currently there are 2 second generation pneumococcal conjugate vaccines (PCVs) targeted at children, the 10-valent pneumococcal conjugate vaccine (PCV-10) and 13-valent pneumococcal conjugate vaccine (PCV-13) available in the market for the preven

APA, Harvard, Vancouver, ISO, and other styles

4

Wong, Kwan-ting, and 王筠婷. "The cost-effectiveness of 13-valent pneumococcal conjugate vaccine for older adults : a systematic review." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2014. http://hdl.handle.net/10722/206978.

Full text

Abstract:

BACKGROUND: Despite the current recommendation by the Centre for Health Protection (CHP)of Hong Kong for adults aged 65 years or above to receive 23-valent pneumococcal polysaccharide vaccine (PPV23), pneumococcal disease(PD) has become the second leading causes of death in Hong Kong. A relatively new pneumococcal vaccine –13-valent pneumococcal conjugate vaccine (PCV13) was approved by the US Food and Drug Administration (FDA) in December 2011 and the European Medicines Agency (EMA) in July 2013 for the prevention of invasive disease caused by S. pneumoniae for older adults aged 50 years or a

APA, Harvard, Vancouver, ISO, and other styles

5

Mitchell, Patrick Kevin. "Pneumococcal Population Dynamics in the Conjugate Vaccine Era." Thesis, Harvard University, 2016. http://nrs.harvard.edu/urn-3:HUL.InstRepos:27201746.

Full text

Abstract:

The introduction of pneumococcal conjugate vaccines (PCVs) in the early years of the 21st century have led to significant changes in pneumococcal epidemiology. Using transmission modeling and genomics based approaches, this dissertation evaluates alterations to the pneumococcal population through the PCV era. Chapter 1 presents a transmission model designed to examine factors that may influence the potential of a previously rare antibiotic resistant lineages to emerge following the introduction of a vaccine targeting more common resistant types, finding that such emergence is more likely in se

APA, Harvard, Vancouver, ISO, and other styles

6

Coulibaly, Aissata. "Impact of Pneumococcal Conjugate Vaccine Thirteen Valent on the Reduction of Invasive Pneumococcal Disease." ScholarWorks, 2016. https://scholarworks.waldenu.edu/dissertations/2116.

Full text

Abstract:

Many children under the age of 5 die each year of invasive pneumococcal disease. Childhood vaccination against this disease reduces morbidity and mortality. Despite the introduction of a pneumococcal conjugate vaccine (PCV13) in a central African country in 2011, all provinces have not yet been vaccinated. The purpose of this quantitative quasi-experimental study was to determine whether there was an association between the introduction of PCV13 and new cases of pneumococcal disease in 2 provinces in central Africa. The sample size for the study was 380. The theoretical framework for this stud

APA, Harvard, Vancouver, ISO, and other styles

7

Perez, Federico. "Challenges And Opportunities To Protect Veterans From Pneumococcal Disease: A “Virtual Clinic” Improves Vaccination." Case Western Reserve University School of Graduate Studies / OhioLINK, 2018. http://rave.ohiolink.edu/etdc/view?acc_num=case1512685624555677.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Wadanambi, Arachchige Sanjay Harsha Jayasinghe. "Long-term impact and effectiveness of vaccines on invasive pneumococcal disease in Australian children." Thesis, The University of Sydney, 2019. http://hdl.handle.net/2123/20156.

Full text

Abstract:

Pneumococcal disease is a leading cause of morbidity and mortality in children globally. Pneumococcal conjugate vaccines (PCVs), available since early 2000, had proven efficacy to prevent invasive pneumococcal disease (IPD)-the sever form of pneumococcal infections. For Australian children PCV had been publicly funded through the national immunisation program, initially in 2001 for those with increased disease risk which included Aboriginal and Torres Strait Islander children and from 2005 for all children. The schedule of PCV used in Australia comprising three doses at age 2, 4 and 6 months (

APA, Harvard, Vancouver, ISO, and other styles

9

Arana, Jorge E. "Comparison of Post-Licensure Safety Surveillance of 13-Valent Pneumococcal Conjugate Vaccine and 7-Valent Pneumococcal Conjugate Vaccine: Data from the Vaccine Advere Event Reporting System (Vaers)." Digital Archive @ GSU, 2011. http://digitalarchive.gsu.edu/iph_theses/159.

Full text

Abstract:

Comparison of Post-licensure safety surveillance of 13-Valent Pneumococcal Conjugate vaccine and 7-Valent Pneumococcal Conjugate vaccine: Data from the Vaccine Adverse Event Reporting System (VAERS). Background: On February 24, 2010, Food and Drug Administration (FDA) licensed a 13-valent pneumococcal conjugate vaccine (Prevnar 13®, [PCV13]) for use among children aged 6 weeks--71 months. The Advisory Committee on Immunization Practices (ACIP) recommended PCV13 routine vaccination of all children aged 2--59 months, children aged 60--71 months with underlying medical conditions, with PCV13

APA, Harvard, Vancouver, ISO, and other styles

10

Kwambana, Brenda Anna. "Infant nasopharyngeal microbial ecology and the pneumococcal conjugate vaccine." Thesis, University of Leicester, 2011. http://hdl.handle.net/2381/10049.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Ohtola, Jennifer A. "Pneumococcal Vaccination in Aging HIV-Infected Individuals." University of Toledo Health Science Campus / OhioLINK, 2015. http://rave.ohiolink.edu/etdc/view?acc_num=mco1435076215.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Li, Tsz-wai, and 李梓維. "Efficacy of combined influenza and 23-valent pneumococcal polysaccharide vaccines in chronic smokers." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2014. http://hdl.handle.net/10722/202310.

Full text

Abstract:

Background Chronic smokers are at risk of premature death associated with underlying pulmonary or cardiovascular diseases. Dual influenza and pneumococcal vaccination has been shown to prevent death and hospitalization secondary to pulmonary or cardiovascular diseases in elderly persons. Its effect in chronic smokers remained unknown. Methods This is a prospective randomized open-labeled trial conducted from April 2010 to March 2013, comprising adult patients aged less than 50 years who were chronic smokers. Subjects were randomly assigned into 4 groups. Group 1 (study group) patients rec

APA, Harvard, Vancouver, ISO, and other styles

13

Chan, Tuen-ching, and 陳端正. "Seasonal influenza and pneumococcal vaccination in institutionalized older adults." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2014. http://hdl.handle.net/10722/207606.

Full text

Abstract:

Influenza (IV) and pneumococcal polysaccharide vaccination (PPV) may reduce hospitalization and mortality but the effectiveness of these vaccines in older adults (≥65 years) is controversial. This thesis includes seven parts with a total of ten studies studying different aspects regarding IV and PPV in institutionalized older adults - the group with the highest infection-related morbidity and mortality. 　　　　In Part I, we presented the controversies about effectiveness of influenza and pneumococcal vaccination in institutionalized older adults. 　　　　In Part II, we studied a retrospective

APA, Harvard, Vancouver, ISO, and other styles

14

Clutterbuck, Elizabeth Ann. "The human B cell response to a pneumococcal conjugate vaccine." Thesis, Open University, 2008. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.446115.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Iyer, Anita Sridhar. "Response to Pneumococcal-Polysaccharide Vaccine PPV23 in HIV-Positive Individuals." University of Toledo Health Science Campus / OhioLINK, 2015. http://rave.ohiolink.edu/etdc/view?acc_num=mco1437416478.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Poerschke, Gabriele. "Key issues of evidence-based vaccinology as illustrated by pneumococcal vaccine development." Thesis, Click to view the E-thesis via HKUTO, 2001. http://sunzi.lib.hku.hk/hkuto/record/B3197076X.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Hamaluba, Mainga. "Streptococcus pneumoniae : nasopharyngeal carriage and vaccine studies in the UK and Nepal." Thesis, University of Aberdeen, 2015. http://digitool.abdn.ac.uk:80/webclient/DeliveryManager?pid=230502.

Full text

Abstract:

Streptococcus pneumoniae is one of the leading causes of morbidity and mortality in children under 5. Low-income countries are disproportionally affected and data in these settings are lacking. Effective strategies to control disease include infant immunisation with pneumococcal protein-polysaccharide conjugate vaccines. However, ongoing surveillance of carriage and disease are important to understand the impact of vaccination within communities. This thesis evaluated nasopharyngeal (NP) carriage in 3 generations, following introduction of the 7-valent pneumococcal conjugate vaccine (PCV7) in

APA, Harvard, Vancouver, ISO, and other styles

18

Kunda, N. K. "Dry powder inhalation of pneumococcal vaccine using polymeric nanoparticles as carriers." Thesis, Liverpool John Moores University, 2014. http://researchonline.ljmu.ac.uk/4462/.

Full text

Abstract:

Streptococcus pneumoniae is the leading bacterial cause of pneumococcal diseases, of which pneumonia is the main cause of death amongst the immunocompromised, elderly over the age of 50 and children under the age of 5. Although vaccines such as pneumococcal polysaccharide vaccine 23, pneumococcal conjugate vaccine 7, 10 and 13 are available, they are expensive to produce and distribute. Moreover, the variation in serotype distribution across geographical locations and rise in dominance of disease due to non-vaccine serotype coverage has led to significant attention towards the development of a

APA, Harvard, Vancouver, ISO, and other styles

19

Skull, Susan. "Effectiveness of influenza and pneumococcal vaccination against hospitalisation for community-acquired pneumonia among persons >65 years /." Connect to thesis, 2007. http://repository.unimelb.edu.au/10187/1998.

Full text

Abstract:

Although there are well-documented benefits from influenza vaccine and 23-valent pneumococcal polysaccharide vaccine (23vPPV) against invasive pneumococcal disease and laboratory confirmed influenza, their effectiveness against pneumonia remains controversial for community-based persons aged >=65years. At the time of this research, within Australia, only the government of Victoria publicly funded these vaccines for elderly persons. With continued growth of the elderly population, the subsequent adoption of an Australia-wide program, and increasing uptake of similar programs in other countries,

APA, Harvard, Vancouver, ISO, and other styles

20

Morrow, Adrienne. "The burden of pneumococcal disease in the Canadian population before routine use of the 7-valent pneumococcal conjugate vaccine." Thesis, Université Laval, 2006. http://www.theses.ulaval.ca/2006/23767/23767.pdf.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Xu, Hui, and 徐晖. "Review on global disease burden of pneumonia in young children and pneumococcal vaccination policy." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2012. http://hub.hku.hk/bib/B48426799.

Full text

Abstract:

Pneumonia is one of the top causes of deaths in children younger than 5 years of age. According to WHO estimation, globally there are nearly 2 millions young children who die from pneumonia every year, and more than 70% of these deaths occurred in Africa and Southeast Asia. Pneumonia caused by Streptococcus pneumoniae (also called pneumococcus) is a vaccine preventable disease, accounting for 39% of community-acquired pneumonia. There are two types of pneumococcal vaccines that are pneumococcal polysaccharide vaccine (PPV) and pneumococcal conjugate vaccines (PCV). The latter one is routinely

APA, Harvard, Vancouver, ISO, and other styles

22

Usuf, Effua Abigail. "The introduction of pneumococcal conjugate vaccine into the Gambia : carriage and costs." Thesis, London School of Hygiene and Tropical Medicine (University of London), 2012. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.590562.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Lock, Robert Arthur. "Studies on virulence proteins of Streptococcus Pneumoniae /." Title page, summary and table of contents only, 1989. http://web4.library.adelaide.edu.au/theses/09PH/09phl813.pdf.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Parameswar, Archana R. "Towards development of a fully synthetic conjugate vaccine investigation of structural analogs of Streptococcus pneumoniae serogroup 6 /." Diss., St. Louis, Mo. : University of Missouri--St. Louis, 2008. http://etd.umsl.edu/r3161.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Vanghelof, Joseph C. "PNEUMOCOCCAL CONJUGATE VACCINE 13 COVERAGE IN CHILDREN, HIGH-RISK ADULTS 19-64 YEARS OF AGE, AND ADULTS OVER 65 YEARS OF AGE IN A COMMERCIALLY INSURED U.S. POPULATION." UKnowledge, 2017. http://uknowledge.uky.edu/pharmacy_etds/76.

Full text

Abstract:

This thesis aimed to elucidate the demographic characteristics associated with elevated or reduced rates of pneumococcal conjugate 13 (PCV13) vaccination. A retrospective cohort study was performed using the Truven Health MarketScan® Database. Three cohorts were created corresponding to populations for which the CDC recommends PCV13 vaccination. Cohort 1: children < 36 months of age. Cohort 2: adults 19-64 years of age with high infection risk. Cohort 3: adults > 65 years of age. Odds of having a PCV13 claim were calculated for each cohort. For Cohort 1, 78% out of a total of 353,214 subjects

APA, Harvard, Vancouver, ISO, and other styles

26

Kyaw, Moe Hein. "Epidemiology of pneumococcal disease in Scotland : implications for vaccine prevention policies and strategies." Thesis, University of Edinburgh, 2003. http://hdl.handle.net/1842/28385.

Full text

Abstract:

Methods: Review of laboratory data collected through a national network of diagnostic laboratories covering the entire population of Scotland, was reviewed to examine the epidemiological characteristics of pneumococcal disease. Cross-sectional surveys were conducted to explore pneumococcal polysaccharide vaccination practices. Results: The incidence of invasive pneumococcal disease is highest in young children aged less than 2 years (44.9/10<sup>5</sup> persons) and in the elderly aged 65 years and above (28.4/10<sup>5</sup>) persons. The incidence of pneumococcal meningitis is highest in chil

APA, Harvard, Vancouver, ISO, and other styles

27

Bahuaud, Mathilde. "Vaccination anti-pneumococcique chez les sujets à risque d'infections invasives à pneumocoques et prévention de l'hyporéponse Immunogenicity and persistence of the 13-valent pneumococcal conjugate vaccine (PCV13) in patients with untreated smoldering multiple myeloma (SMM): a pilot study Immunogenicity and persistence of a prime-boost re-vaccination strategy for pneumococcal vaccines in patients with rheumatoid arthritis Pneumococcal vaccination in patients with systemic lupus erythematosus: a multicenter placebo-controlled randomized double-blind study Prevention of hyporesponsiveness by modulation of schedule and doses of pneumococcal vaccine immunization." Thesis, Sorbonne Paris Cité, 2018. http://www.theses.fr/2018USPCB067.

Full text

Abstract:

Deux vaccins sont actuellement disponibles pour la prévention des infections invasives à pneumocoques (IIP) : un vaccin polysaccharidique Pneumovax® (PPV23) et un vaccin conjugué Prevenar13® (PCV13), induisant respectivement une protection contre 23 et 13 sérotypes. Le PPV23 est considéré comme faiblement immunogène, en particulier chez les personnes âgées et les patients immunodéprimés. Le PCV13, en revanche, en raison de la conjugaison à une protéine porteuse, présente l'avantage d'induire une réponse immunitaire T-dépendante, non observée avec le vaccin PPV23. Dans notre travail nous avons

APA, Harvard, Vancouver, ISO, and other styles

28

Tunc, Melissa. "Evidence-Based Practice for Influenza and Pneumococcal Nurse-Driven Protocol." ScholarWorks, 2018. https://scholarworks.waldenu.edu/dissertations/5142.

Full text

Abstract:

At the project site in New Jersey, eligible patients were leaving the hospital without receiving the influenza or pneumococcal vaccine. The field site has an established, evidence-based, nurse-driven protocol. The purpose of this project was to increase adherence to the current influenza and pneumococcal nurse-driven protocol on one medical-surgical unit. This unit had experienced low adherence rates to the nurse-driven protocol for vaccines, not reaching the New Jersey state target of 96% administration prior to discharge. The practice-focused question was: Will increasing awareness of eviden

APA, Harvard, Vancouver, ISO, and other styles

29

Vadesilho, Cintia Fiuza Marques. "Mapeamento de epitopos presentes em variantes dos antígenos vacinais PspA (Pneumococcal surface protein A) e PspC (Pneumococcal surface protein C) de Streptococcus pneumoniae." Universidade de São Paulo, 2014. http://www.teses.usp.br/teses/disponiveis/87/87131/tde-06122014-075950/.

Full text

Abstract:

S. pneumoniae pode causar infecções do trato respiratório. Uma alternativa às vacinas conjugadas, que conferem proteção sorotipo-específica, seria uma vacina baseada em epitopos de diferentes variantes de antígenos como PspA e PspC. O objetivo deste trabalho foi a identificação de epitopos de variantes de PspA e PspC, utilizando a técnica peptide array, visando a síntese de um antígeno composto por múltiplos epitopos. Os resultados obtidos indicaram que anticorpos contra epitopos lineares de PspA reconhecem as regiões inicial N-terminal e rica em prolinas, mas estes epitopos parecem ser apenas

APA, Harvard, Vancouver, ISO, and other styles

30

Greenfield, Hayley Maria. "Evaluation of pneumococcal conjugate vaccine (Prevenar®) inpatients with myeloma and chronic lymphocytic leukaemia." Thesis, University of Manchester, 2009. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.507207.

Full text

Abstract:

Infection with Streptococcus pneu1110niae is responsible for significant mortality in individuals with a defective humoral response. This diverse group includes patients with the haematological conditions myeloma and chronic lymphocytic leukaemia. Vaccination to prevent pneumococcal infection is recommended by the Department of Health for those individuals in whom disease is likely to be 'more common and/or more dangerous'. The currently recommended 23-valent polysaccharide vaccine has been shown to be poorly immunogenic in patients with myeloma and chronic lymphocytic leukaemia. Responses to

APA, Harvard, Vancouver, ISO, and other styles

31

Moss, Samantha Jane. "Immunogenicity of the seven valent conjugate in UK term and preterm infants pneumococcal vaccine." Thesis, University of Newcastle upon Tyne, 2008. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.485803.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Jaccard, Ruedin Hélène. "Invasive meningococcal and pneumococcal disease in Switzerland : cost-utility analysis of different vaccine strategies /." Neuchâtel : [s.n.], 2003. http://www.public-health-edu.ch/new/Abstracts/JRH_02.06.03.pdf.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Tashani, Mohamed Nagmi. "Optimising Immune Responses To Conjugate Vaccines Among Vulnerable Populations: Infants And Hajj Travellers." Thesis, The University of Sydney, 2017. http://hdl.handle.net/2123/17307.

Full text

Abstract:

Conjugate vaccines have been developed against some bacterial pathogens such as Haemophilus influenzae type b (Hib), Neisseria meningitidis, and Streptococcus pneumoniae. Conjugate vaccines are immunologically superior to the polysaccharides vaccines, but more expensive. They involve the joining of a purified polysaccharide moiety of bacterial capsule to a protein molecule known as carrier protein. The carrier protein enables the vaccines to elicit a T-cell response and thereby induce memory. The carrier protein has antigenic similarity to the components of diphtheria, tetanus and pertussis va

APA, Harvard, Vancouver, ISO, and other styles

34

Baynam, Gareth. "Genetic influences on vaccine response in children." University of Western Australia. School of Paediatrics and Child Health, 2008. http://theses.library.uwa.edu.au/adt-WU2008.0259.

Full text

Abstract:

Vaccination is one of the most efficacious public health interventions1 and has been increasingly used to combat non-infectious diseases. Mechanisms underlying vaccine responses overlap with those regulating immune responses in health and disease. Therefore, an understanding of mechanisms underpinning these responses will have broad implications. Variation in immune response genes contributes to impaired vaccine responses2-4. Understanding the contribution of genetic variants to vaccine responses is likely to be particularly important in early life given the generalized functional immaturity o

APA, Harvard, Vancouver, ISO, and other styles

35

Elemraid, Mohamed Ahmed. "The impact of the pneumococcal conjugate vaccine on the epidemiology and aetiology of childhood pneumonia." Thesis, University of Newcastle upon Tyne, 2013. http://hdl.handle.net/10443/2026.

Full text

Abstract:

Background: The 7-valent pneumococcal conjugate vaccine (PCV7) was introduced routinely in the UK in September 2006 and replaced by PCV13 from April 2010. Aims: To evaluate the impact of PCV7 on the incidence of all-cause community-acquired pneumonia (CAP) in children. Also to investigate the aetiology of CAP before and after the introduction of PCV as well as serotype the pneumococcal infections. Methods: Enrolled children were from North East England (excluding Cumbria) who were aged 0–16 years and presented with clinical and radiological features suggestive of pneumonia. Epidemiology survey

APA, Harvard, Vancouver, ISO, and other styles

36

Puumalainen, Taneli. "An eleven valent diphtheria and tetanus-conjugated pneumococcal vaccine immunogenicity and safety in Filipino infants." Helsinki : University of Helsinki, 2003. http://ethesis.helsinki.fi/julkaisut/laa/kliin/vk/puumalainen/.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Mezones, Holguín Edward, Aybara Carlos Canelo, Clark Andrew David, et al. "Cost-effectiveness analysis of 10- and 13-valent pneumococcal conjugate vaccines in Peru." Elsevier B.V, 2015. http://hdl.handle.net/10757/582635.

Full text

Abstract:

Objective To evaluate the cost-effectiveness of introducing the 10-valent pneumococcal conjugate vaccine (PCV10) versus the 13-valent PCV (PCV13) to the National Immunization Schedule in Peru for prevention of pneumococcal disease (PD) in children <5 years of age. Methods The integrated TRIVAC vaccine cost-effectiveness model from the Pan American Health Organization's ProVac Initiative (version 2.0) was applied from the perspective of the Government of Peru. Twenty successive cohorts of children from birth to 5 years were evaluated. Clinical outcomes were pneumococcal pneumonia (PP),

APA, Harvard, Vancouver, ISO, and other styles

38

Webb, Silky Fanyelle. "Hospitalizations associated with pneumococcal infection within the Medicare population among vaccinated and non-vaccinated patients." [Tampa, Fla.] : University of South Florida, 2007. http://purl.fcla.edu/usf/dc/et/SFE0002032.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Mastrodomenico, Jessica. "An Examination of the Socio-Demographic Characteristics Associated with Adult Vaccination Prevalence for Preventable Diseases in the United States." Digital Archive @ GSU, 2010. http://digitalarchive.gsu.edu/iph_theses/93.

Full text

Abstract:

JESSICA MASTRODOMENICO An Examination of the Socio-Demographic Characteristics Associated with Adult Vaccination Prevalence for Preventable Diseases in the United States Background: An estimated 50,000 adults in the United States (U.S.) die each year from one of 10 vaccine preventable diseases. For those who survive vaccine preventable infections, health care costs and loss of income become more significant. While children in the U.S. aged 0-2 exhibit vaccine prevalence rates of almost 90%, some adult vaccine prevalence rates in the U.S. population are reported to be nearly 30-40% less than

APA, Harvard, Vancouver, ISO, and other styles

40

Glover, David Tawayne. "Pneumococcal choline-binding protein A its role in virulence and its utility as a Streptococcus pneumoniae vaccine antigen /." Thesis, Birmingham, Ala. : University of Alabama at Birmingham, 2007. https://www.mhsl.uab.edu/dt/2007p/glover.pdf.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

O'Grady, Kerry-Ann. "Pneumonia in Indigenous children in the Northern Territory, Australia, and the effectiveness of pneumococcal conjugate vaccine : 1997 - 2005." Thesis, University of Melbourne, 2008. http://purl.org/au-research/grants/nhmrc/359341.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Silva, Junior Jailton de Azevedo. "Impacto da vacina pneumocócica conjugada 10-valente (PCV10) na meningite pneumocócica na região metropolitana de Salvador, Bahia." reponame:Repositório Institucional da FIOCRUZ, 2015. https://www.arca.fiocruz.br/handle/icict/14244.

Full text

Abstract:

Submitted by Ana Maria Fiscina Sampaio (fiscina@bahia.fiocruz.br) on 2016-05-11T14:07:03Z No. of bitstreams: 1 Jailton_Azevedo Silva Junior. Impacto da vacina...2015.pdf: 2256825 bytes, checksum: 6da623ba97a2d68604f3b4a098585b07 (MD5)<br>Approved for entry into archive by Ana Maria Fiscina Sampaio (fiscina@bahia.fiocruz.br) on 2016-05-11T14:07:15Z (GMT) No. of bitstreams: 1 Jailton_Azevedo Silva Junior. Impacto da vacina...2015.pdf: 2256825 bytes, checksum: 6da623ba97a2d68604f3b4a098585b07 (MD5)<br>Made available in DSpace on 2016-05-11T14:07:15Z (GMT). No. of bitstreams: 1 Jailton_Azevedo Sil

APA, Harvard, Vancouver, ISO, and other styles

43

Veras, Maria Amélia de Sousa Mascena. "Um estudo caso-controle da efetividade da vacina polissacarídica antipneumococo em adultos infectados pelo HIV, São Paulo, Brasil." Universidade de São Paulo, 2005. http://www.teses.usp.br/teses/disponiveis/5/5137/tde-10102014-102755/.

Full text

Abstract:

Introdução: Pessoas infectadas pelo vírus da imunodeficiência humana (HIV) têm alto risco de desenvolver doença pneumocócica. Infecções invasivas pelo Streptococcus pneumoniae (pneumococo) lideram a morbidade e a mortalidade entre crianças, idosos e pessoas com doenças de base que comprometem o sistema imune ou diminuem a função esplênica. A infecção pelo HIV está associada a um aumento de até dez vezes na incidência das pneumonias bacterianas no mundo. S. pneumoniae é o agente mais comum identificado. A imunização contra S. pneumoniae tem sido recomendada para indivíduos infectados pelo HIV e

APA, Harvard, Vancouver, ISO, and other styles

44

Francis, Jacinta Piwen. "Maternal and neonatal immune responses to pneumococcal protein antigens in relation to risk for early upper respiratory tract (URT) pneumococcal carriage in a high-risk population in Papua New Guinea." University of Western Australia. School of Paediatrics and Child Health, 2009. http://theses.library.uwa.edu.au/adt-WU2010.0025.

Full text

Abstract:

[Truncated abstract] Pneumococcal exposure is high and life-long in developing countries including Papua New Guinea (PNG), with children under 2 years of age being at most risk for early upper respiratory tract pneumococcal carriage and infection. Deaths from pneumococcal diseases such as pneumonia and meningitis are common and likely the result of an absence of vaccination programmes. The need for effective and affordable pneumococcal vaccines has led to the testing of protein antigens including pneumolysin (Ply) and pneumococcal surface protein A (PspA) as novel vaccine antigens. Little is k

APA, Harvard, Vancouver, ISO, and other styles

45

Frazão, Nelson. "Massive shift in the pneumococcal nasopharyngeal flora after the 7-valent conjugate vaccine: epidemiological studies and testing pathogenic potential in animal models." Doctoral thesis, Universidade Nova de Lisboa. Instituto de Tecnologia Química e Biológica, 2010. http://hdl.handle.net/10362/5792.

Full text

Abstract:

Dissertation presented to obtain the PhD degree in Biology/Molecular Biology by Universidade Nova de Lisboa, Instituto de Tecnologia Química e Biológica<br>Although it exists mostly as a commensal bacterium colonizing the human nasopharynx, particularly in children, the Gram-positive bacterium Streptococcus pneumoniae, is also a major human pathogen that can cause a wide range of diseases, which include otitis media, sinusitis, pneumonia, and such life-threatening afflictions as bloodstream infection and meningitis. Created to protect children against pneumococcal disease, the 7-valent p

APA, Harvard, Vancouver, ISO, and other styles

46

Tostes, Rafaella Oliveira. "Avaliação da eficácia do antígeno PspA (Pneumococcal surface protein A) em modelo de co-colonização com diferentes linhagens de Streptococcus pneumoniae." Universidade de São Paulo, 2016. http://www.teses.usp.br/teses/disponiveis/87/87131/tde-25082016-102810/.

Full text

Abstract:

Streptococcus pneumoniae é o patógeno causador de diversas doenças com alta mortalidade e morbidade, como meningite e pneumonia. As vacinas disponíveis baseiam-se na resposta contra o polissacarídeo capsular (PS), porém possuem elevado custo e cobertura limitada aos sorotipos vacinais. O objetivo deste estudo foi avaliar a eficácia da imunização nasal com PspAs recombinantes de família 1 (rPspA1 e rPspA2) e de família 2 (rPspA3, rPspA4 e rPspA5) em um modelo de cocolonização da nasofaringe de camundongos, utilizando isolados que expressam diferentes PspAs (PspA1 ao PspA4). Esse modelo visa ana

APA, Harvard, Vancouver, ISO, and other styles

47

Ouldali, Naïm. "Impact à moyen terme de l'implémentation du vaccin conjugué pneumococcique 13 valences en pédiatrie : analyse de séries chronologiques interrompues." Thesis, Université de Paris (2019-....), 2020. https://wo.app.u-paris.fr/cgi-bin/WebObjects/TheseWeb.woa/wa/show?t=4437&f=28972.

Full text

Abstract:

Introduction. Le bénéfice à moyen terme de l’implémentation des vaccins pneumococciques conjugués (VPCs) reste à préciser, du fait du remplacement sérotypique. Nous avons évalué en France, chez l’enfant, l’impact à moyen terme des VPC sur : (i) les méningites à pneumocoque, (ii) les pneumopathies aiguës communautaires (PAC), (iii) la dynamique de résistance aux antibiotiques des sérotypes pneumococciques dans le portage naso-pharyngé. Nous avons également évalué la qualité méthodologique de la littérature concernant l’impact des VPCs sur les infections pneumococciques. Méthodes. Nous avons exp

APA, Harvard, Vancouver, ISO, and other styles

48

Svensson, Tobias. "Infectious and bleeding complications in patients with hematological malignancies : Studies on diagnosis and prevention." Doctoral thesis, Uppsala universitet, Hematologi, 2017. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-316461.

Full text

Abstract:

The overall aim of this thesis is to improve knowledge about the prevention of infectious and bleeding complications in patients with hematological malignancies, primarily in those with chronic lymphocytic leukemia (CLL) and myelodysplatic syndrome (MDS). Hypogammaglobulinemia, impaired production of immunoglobulins (Ig), is an established risk factor for infection, but the impact of IgG pure subclass deficiency (IgG subclass deficiency with adequate production of IgG, IgA, and IgM) has been debated. In a retrospective single institution study, we concluded that pure IgG subclass deficiency in

APA, Harvard, Vancouver, ISO, and other styles

49

Fernández, de Sevilla Estrach Mariona. "Características clínicas y microbiológicas de la enfermedad neumocócica invasiva pediátrica en Barcelona en la era de la vacuna heptavalente conjugada." Doctoral thesis, Universitat de Barcelona, 2012. http://hdl.handle.net/10803/107675.

Full text

Abstract:

La enfermedad neumocócica invasiva (ENI) constituye un problema grave de Salud Pública en la edad infantil, con una morbimortalidad considerable. En los últimos años se han introducido vacunas adecuadas para la edad infantil (año 2001:vacuna heptavalente conjugada, PCV7, año 2010:vacunas decavalente y trecevalente conjugadas). Desde la comercialización de la PCV7 se ha observado una emergencia de la ENI por serotipos no incluidos en la PCV7 (SNV) en nuestro medio. Esta tesis pretende a partir del análisis de la ENI que ha tenido lugar en los últimos años en nuestro medio (cuando la PCV7 era l

APA, Harvard, Vancouver, ISO, and other styles

50

Campos, Ivana Barros de. "Otimização do processo de produção e caracterização da vacina celular contra Streptococcus pneumoniae." Universidade de São Paulo, 2014. http://www.teses.usp.br/teses/disponiveis/87/87131/tde-19022015-093553/.

Full text

Abstract:

S. pneumoniae é um patógeno de grande impacto em saúde pública e vacinas comerciais têm cobertura limitada e alto custo. Como alternativa, desenvolveu-se uma vacina celular de baixo custo, cuja produção envolve apenas a separação das bactérias do caldo e sua inativação. Neste trabalho, foram avaliados processos descontínuo, descontínuo alimentado e contínuo com reciclo de células, cuja produção de biomassa foi 3 vezes maior que a do descontínuo. Vacinas obtidas nos 3 processos foram utilizadas em ensaios de imunização de camundongos e induziram níveis similares de IgG e IL-17A. Anticorpos liga

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!